Apovian CM. Prediabetes: a new indication for GLP-1s? Int J Obes 2025. https://doi.org/10.1038/s41366-025-01930-2

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. https://doi.org/10.1056/NEJMoa012512.

Article  CAS  PubMed  Google Scholar 

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. Three years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–409. https://doi.org/10.1016/S0140-6736(17)30069-7.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563.

Article  CAS  PubMed  Google Scholar 

Bannuru RR. ADA Professional Practice Committee. Introduction and methodology: Standards of Care in Overweight and Obesity—2025. BMJ Open Diabetes Res Care. 2025;13:e004928. https://doi.org/10.1136/bmjdrc-2025-00492810/10/2025.

Article  PubMed  Google Scholar